Home > Novo Nordisk Inc. (NNI) Products > Obesity Products
Novo Nordisk Inc. (NNI) Products
Novo Nordisk has multiple products on the market for the treatment of Diabetes, Obesity, Growth Hormone Disorders, Hemophilia and Rare Bleeding Disorders. Access information and resources on each of our products below.
Obesity
Wegovy™
(semaglutide) injection 2.4 mg
Wegovy™ (semaglutide) injection is initiated at a dose of 0.25 mg once weekly for 4 weeks. The dose should be increased at 4-week intervals, following the dose escalation schedule, until a dose of 2.4 mg once weekly is reached. For more information about the dose escalation schedule for Wegovy™, please see the Prescribing Information.
Wegovy™ (semaglutide) injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).
Saxenda®
(liraglutide) injection 3 mg
Saxenda® (liraglutide) injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) and in pediatric patients aged 12 years and older with body weight above 60 kg and an initial BMI corresponding to 30 kg/m2 or greater for adults (obese) by international cut-offs.
obesity
Additional Information
Speak to a live medical representative.
If you are a healthcare provider from the United States, click below to request information directly from the Novo Nordisk Medical Information department. If you are a patient, please visit here to contact us, or call 1-800-727-6500.
Search the Medical Information Database
The Scientific Exchange is a resource for U.S. Healthcare Professionals to learn more about disease states investigated by Novo Nordisk and our related products.
Scientific Exchange is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.
